Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit

Documenti analoghi

• Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
  di: Tarhini, Ahmad A., et al.
  Pubblicazione: (2014)
• Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
  di: Retseck, Janet, et al.
  Pubblicazione: (2016)
• Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
  di: Tarhini, Ahmad A., et al.
  Pubblicazione: (2015)
• A unique gene expression signature is significantly differentially expressed in tumor positive or negative sentinel lymph nodes in patients with melanoma
  di: Tarhini, Ahmad A, et al.
  Pubblicazione: (2017)
• A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
  di: Tarhini, Ahmad A, et al.
  Pubblicazione: (2014)